As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of
the potential adverse effects of these drugs continues to broaden. Emerging evidence …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …

It is disheartening for parents to discover that their children have long-term cardiac
dysfunction after being cured of life-threatening childhood cancers. As the number of …

Advances in cancer therapeutics have led to dramatic improvements in survival, now
inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities …

2D (Two-dimensional), 3D (Three-dimensional), ASE (American Society of
Echocardiography), CAC (Coronary artery calcium), CCT (Cardiovascular computed …

The development of cardiotoxicity induced by cancer treatments has emerged as a
significant clinical problem, both in the short run, as it may influence drug administration in …

Abstract Purpose of the Review Even as immune checkpoint inhibitors (ICIs) have
transformed the lifespan of many patients, they may also trigger acceleration of long-term …

During the last 30 years, we have assisted to a great implementation in anticancer treatment
with a subsequent increase of cancer survivors and decreased mortality. This has led to an …

Anthracyclines are among the most frequently utilized anti-cancer therapies; however, their
use is frequently associated with off-target cardiotoxic effects. Cardiac computed …